A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
NCT02482441
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Relapsed Tumors
Refractory Solid Tumors
Interventions
DRUG:
OMP-131R10
DRUG:
FOLFIRI
Sponsor
OncoMed Pharmaceuticals, Inc.